Key features of the intragraft microenvironment that determine long-term survival following transplantation

Frontiers in Immunology

Volumn 3, Issue APR, 2012, Pages

  Bruneau, Sarah ^a,b   Woda, Craig Bryan ^a,b   Daly, Kevin Patrick ^a,b   Boneschansker, Leonard ^a,b   Jain, Namrata Gargee ^a,b   Kochupurakkal, Nora ^a,b   Contreras, Alan Gabriel ^a,b   Seto, Tatsuichiro ^a,b   Briscoe, David Michael ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Allograft rejection; Allograft vasculopathy; Angiogenesis; Chronic allograft rejection; Endothelial cell; Hypoxia; Microvascular injury; Vascular endothelial growth factor

Indexed keywords

EID: 84870647577     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00054     Document Type: Review

References (166)

1. Abramson, L. P., Pahl, E., Huang, L., Stellmach, V., Rodgers, S., Mavroudis, C., Backer, C. L., Arensman, R. M., and Craw-ford, S. E. (2002). Serum Vascular endothelial growth factor as a surveillance marker for cellular rejection in pediatric cardiac transplantation. Transplantation 73, 153-156.
2. Alon, T., Hemo, I., Itin, A., Pe'Er, J., Stone, J., and Keshet, E. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 1024-1028.
3. Amano, K., Okigaki, M., Adachi, Y., Fujiyama, S., Mori, Y., Kosaki, A., Iwasaka, T., and Matsubara, H. (2004). Mechanism for IL- 1 beta-mediated neovascularization unmasked by IL-1 beta knock-out mice. J. Mol. Cell. Cardiol. 36, 469-480.
4. Arciniegas, E., Sutton, A. B., Allen, T. D., and Schor, A. M. (1992). Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J. Cell. Sci. 103(Pt 2), 521-529.
5. Arora, S., Ueland, T., Wennerblom, B., Sigurdadottir,V.,Eiskjaer,H.,Botker, H. E., Ekmehag, B., Jansson, K., Mortensen, S. A., Saunamaki, K., Simonsen, S., Gude, E., Bendz, B., Solbu, D., Aukrust, P., and Gullestad, L. (2011). Effect of everolimus intro- duction on cardiac allograft vascu- lopathy - results of a randomized, multicenter trial. Transplantation 92, 235-243.
6. Atkinson, C., Southwood, M., Pitman, R., Phillpotts, C., Wallwork, J., and Goddard, M. (2005). Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopa- thy. J. Heart Lung Transplant. 24, 551-558.
7. Auerbach, R., and Sidky, Y. A. (1979). Nature of the stimulus leading to lymphocyte-induced angiogenesis. J. Immunol. 123, 751-754.
8. Aydin, Z., van Zonneveld, A. J., de Fijter, J. W., and Rabelink, T. J. (2007). New horizons in prevention and treatment of ischaemic injury to kidney transplants. Nephrol. Dial. Transplant. 22, 342-346.
9. Babu, A. N., Murakawa, T., Thurman, J. M., Miller, E. J., Henson, P. M., Zamora, M. R., Voelkel, N. F., and Nicolls, M. R. (2007). Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. J. Clin. Invest. 117, 3774-3785.
10. Barleon, B., Sozzani, S., Zhou, D., Weich, H. A., Mantovani, A., and Marme, D. (1996). Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-3343.
11. Basu, A., Hoerning, A., Datta, D., Edel- bauer, M., Stack, M. P., Calzadilla, K., Pal, S., and Briscoe, D. M. (2010). Cutting edge: vascular endothelial growth factor-mediated signal- ing in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN- gamma production. J. Immunol. 184, 545-549.
12. Basu, S., Nagy, J. A., Pal, S., Vasile, E., Eckelhoefer, I. A., Bliss, V. S., Manseau, E. J., Dasgupta, P. S., Dvorak, H. F., and Mukhopad- hyay, D. (2001). The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat. Med. 7, 569-574.
13. Bishop, G. A., Waugh, J. A., Lan-ders, D. V., Krensky, A. M., and Hall, B. M. (1989). MicroVascular destruction in renal transplant rejection. Transplantation 48, 408-414.
14. Booth, A. J., and Bishop, D. K. (2010). TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy 2, 511-520.
15. Boulday, G., Haskova, Z., Reinders, M. E., Pal, S., and Briscoe, D. M. (2006). Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. J. Immunol. 176, 3098-3107.
16. Bourbie-Vaudaine, S., Blanchard, N., Hivroz, C., and Romeo, P. H. (2006). Dendritic cells can turn CD4+ T lymphocytes into vascular endothelial growth factor-carrying cells by intercellular neuropilin-1 transfer. J. Immunol. 177, 1460-1469.
17. Briscoe, D. M., Alexander, S. I., and Lichtman, A. H. (1998). Interactions between T lymphocytes and endothelial cells in allograft rejection. Curr. Opin. Immunol. 10, 525-531.
18. Briscoe, D. M., Dharnidharka, V. R., Isaacs, C., Downing, G., Prosky, S., Shaw, P., Parenteau, N. L., and Hardin-Young, J. (1999). The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejection. Transplantation 67, 1590-1599.
19. Briscoe, D. M., and Pal, S. (2008). Assessing the vascular effects of early erythropoietin use in pediatric renal transplant recipients. Nat. Clin. Pract. Nephrol. 4, 136-137.
20. Briscoe, D. M., and Sayegh, M. H. (2002). A rendezvous before rejection: where do T cells meet transplant antigens? Nat. Med. 8, 220-222.
21. Brown, L. F., Detmar, M., Claffey, K., Nagy, J. A., Feng, D., Dvorak, A. M., and Dvorak, H. F. (1997). Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79, 233-269.
22. Brown, L. F., Olbricht, S. M., Berse, B., Jackman, R. W., Matsueda, G., Tognazzi, K. A., Manseau, E. J., Dvorak, H. F., and Van de Water, L. (1995). Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitiv- ity skin reactions. J. Immunol. 154, 2801-2807.
23. Bruder, D., Probst-Kepper, M., Westen-dorf, A. M., Geffers, R., Beissert, S., Loser, K., von Boehmer, H., Buer, J., and Hansen, W. (2004). Neuropilin- 1: a surface marker of regulatory T cells. Eur. J. Immunol. 34, 623-630.
24. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
25. Catalano, A., Caprari, P., Moretti, S., Faronato, M., Tamagnone, L., and Procopio, A. (2006). Semaphorin- 3A is expressed by tumor cells and alters T-cell signal transduction and function. Blood 107, 3321-3329.
26. Chapoval, S. P., Lee, C. G., Tang, C., Kee-gan, A. D., Cohn, L., Bottomly, K., and Elias, J. A. (2009). Lung vascu-lar endothelial growth factor expression induces local myeloid dendritic cell activation. Clin. Immunol. 132, 371-384.
27. Chiodoni, C., Iezzi, M., Guiducci, C., Sangaletti, S., Alessandrini, I., Ratti, C., Tiboni, F., Musiani, P., Granger, D. N., and Colombo, M. P. (2006). Triggering CD40 on endothelial cells contributes to tumor growth. J. Exp. Med. 203, 2441-2450.
28. Choi, Y. J., Chakraborty, S., Nguyen, V., Nguyen, C., Kim, B. K., Shim, S. I., Suki, W. N., and Truong, L. D. (2000). Peritubular capillary loss is associated with chronic tubulointerstitial injury in human kidney: altered expression of Vascular endothelial growth factor. Hum. Pathol. 31, 1491-1497.
29. Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J., and Risau, W. (1996). The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271, 17629-17634.
30. Contreras, A. G., and Briscoe, D. M. (2007). Every allograft needs a silver lining. J. Clin. Invest. 117, 3645-3648.
31. Contreras, A. G., Dormond, O., Edel-bauer, M., Calzadilla, K., Hoern-ing, A., Pal, S., and Briscoe, D. M. (2008). mTOR-understanding the clinical effects. Transplant. Proc. 40, S9-S12.
32. Cotran,R. S. (1994)."Inflammation and repair," in Pathologic Basis of Disease, eds R. S. Cotran, V. Kumar, and S. L. Robbins (Philadelphia: W. B. Saunders), 51-92.
33. Daly, K., Seifert, M., Stack, M., Chan-draker, A., Zurakowski, D., Nohria, A., Givertz, M., Karumanchi, A., and Briscoe, D. M. (2011). Identification of highly sensitive and specific biomarker panel for the diagnosis of chronic rejection/allograft vasculopathy following human cardiac transplantation. Am. J. Transplant. 11, 68-69.
34. Denton, M. D., Davis, S. F., Baum, M. A., Melter, M., Reinders, M. E., Exeni, A., Samsonov, D. V., Fang, J., Ganz, P., and Briscoe, D. M. (2000). The role of the graft endothelium in transplant rejection: evidence that endothelial activation may serve as a clinical marker for the development of chronic rejection. Pediatr. Transplant. 4, 252-260.
35. Denton, M. D., Magee, C., Melter, M., Dharnidharka, V. R., Sayegh, M. H., and Briscoe, D. M. (2004). TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation 78, 1218-1221.
36. Detmar, M., Brown, L. F., Schon, M. P., Elicker, B. M., Velasco, P., Richard, L., Fukumura, D., Mon-sky, W., Claffey, K. P., and Jain, R. K. (1998). Increased microvascular density and enhanced leuko-cyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol. 111, 1-6.
37. Detoraki, A., Granata, F., Staibano, S., Rossi, F. W., Marone, G., and Genovese, A. (2010). Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy 65, 946-958.
38. Dias, S., Hattori, K., Zhu, Z., Heis- sig, B., Choy, M., Lane, W., Wu, Y., Chadburn, A., Hyjek, E., Gill, M., Hicklin, D. J., Witte, L., Moore, M. A., and Rafii, S. (2000). Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106, 511-521.
39. Dormond, O., Contreras, A. G., Mei- jer, E., Datta, D., Flynn, E., Pal, S., and Briscoe, D. M. (2008). CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo. J. Immunol. 181, 8088-8095.
40. Dormond, O., Madsen, J. C., and Briscoe, D. M. (2007). The effects of mTOR-Akt interactions on anti- apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 282, 23679-23686.
41. Duh,E.,andAiello,L. P. (1999).Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48, 1899-1906.
42. Edelbauer, M., Datta, D., Vos, I. H., Basu, A., Stack, M. P., Reinders, M. E., Sho, M., Calzadilla, K., Ganz, P., and Briscoe, D. M. (2010). Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood 116, 1980-1989.
43. Ezaki, T., Baluk, P., Thurston, G., La Barbara, A., Woo, C., and McDonald, D. M. (2001). Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. Am. J. Pathol. 158, 2043-2055.
44. Fava, R. A., Olsen, N. J., Spencer-Green, G., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Senger, D. R., Dvorak, H. F., and Brown, L. F. (1994). Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180, 341-346.
45. Ferrara, N. (2005). The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 209-231.
46. Ferrara, N., and Alitalo, K. (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359-1364.
47. Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442.
48. Ferrara, N., and Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature 438, 967-974.
49. Fine, L. G., and Norman, J. T. (2008). Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 74, 867-872.
50. Folkman, J. (1995a). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
51. Folkman, J. (1995b). Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333, 1757-1763.
52. Folkman, J., and Brem, H. (1992). "Angiogenesis and inflammation,"in Inflammation: Basic Principles and Clinical Correlates, eds J. I. Gallin, I. M. Goldstein, and R. Synderman (New York: Raven Press), 821-839.
53. Freeman, M. R., Schneck, F. X., Gagnon, M. L., Corless, C., Soker, S., Nikne-jad, K., Peoples, G. E., and Klags- brun, M. (1995). Peripheral blood T lymphocytes and lymphocytes infil- trating human cancers express vascular endothelial growth factor: a potential role for T cells in angio-genesis. Cancer Res. 55, 4140-4145.
54. Fukumura, D., and Jain, R. K. (2007). Tumor microvasculature and microenvironment: targets for antiangiogenesis and normalization. Microvasc. Res. 74, 72-84.
55. Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., and Carbone, D. P. (1998). Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166.
56. Gerber, H. P., Hillan, K. J., Ryan, A. M., Kowalski, J., Keller, G. A., Rangell, L., Wright, B. D., Radtke, F., Aguet, M., and Ferrara, N. (1999). VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159.
57. Giraudo, E., Primo, L., Audero, E., Gerber, H. P., Koolwijk, P., Soker, S., Klagsbrun, M., Ferrara, N., and Bussolino, F. (1998). Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co- receptor neuropilin-1 in human vascular endothelial cells. J. Biol. Chem. 273, 22128-22135.
58. Girnita, D. M., Brooks, M. M., Web- ber, S. A., Burckart, G. J., Fer- rell, R., Zdanowicz, G., DeCroo, S., Smith, L., Chinnock, R., Canter, C., Addonizio, L., Bernstein, D., Kirklin, J. K., Ranganathan, S., Naftel, D., Girnita, A. L., and Zeevi, A. (2008). Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi- institutional study. Transplantation 85, 1632-1639.
59. Goel,S.,Duda,D. G.,Xu,L.,Munn,L. L., Boucher, Y., Fukumura, D., and Jain, R. K. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071-1121.
60. Griga, T., Voigt, E., Gretzer, B., Brasch, F., and May, B. (1999). Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 46, 920-923.
61. Halloran, P. F., de Freitas, D. G., Einecke, G., Famulski, K. S., Hidalgo, L. G., Mengel, M., Reeve, J., Sellares, J., and Sis, B. (2010). The molecular phenotype of kidney transplants. Am. J. Transplant. 10, 2215-2222.
62. Hanto, D. W., Maki, T., Yoon, M. H., Csizmadia, E., Chin, B. Y., Gallo, D., Konduru, B., Kuramitsu, K., Smith, N. R., Berssenbrugge, A., Attanasio, C., Thomas, M., Wegiel, B., and Otterbein, L. E. (2010). Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in Swine. Am. J. Transplant. 10, 2421-2430.
63. Hashimoto, N., Phan, S. H., Imaizumi, K., Matsuo, M., Nakashima, H., Kawabe, T., Shimokata, K., and Hasegawa, Y. (2010). Endothelial- mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 43, 161-172.
64. Hoshino, M., Takahashi, M., and Aoike, N. (2001). Expression of Vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asth- matic airways and its relationship to angiogenesis. J. Allergy Clin. Immunol. 107, 295-301.
65. Huang, S. P., Wu, M. S., Shun, C. T., Wang, H. P., Lin, M. T., Kuo, M. L., and Lin, J. T. (2004). Interleukin- 6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J. Biomed. Sci. 11, 517-527.
66. Humphreys, B. D., Lin, S. L., Kobayashi, A., Hudson, T. E., Nowlin, B. T., Bonventre, J. V., Valerius, M. T., McMahon, A. P., and Duffield, J. S. (2010). Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97.
67. Ingulli, E., Alexander, S. I., and Briscoe, D. M. (2009). "Transplantation immunology," in Pediatric Nephrology,eds E. D.Avner,W. E. Harmon,P. Niaudet, and N. Yoshikawa (Berlin: Springer-Verlag), 1835-1866.
68. Inoue, M., Itoh, H., Ueda, M., Naruko, T., Kojima, A., Komatsu, R., Doi, K., Ogawa, Y., Tamura, N., Takaya, K., Igaki, T., Yamashita, J., Chun, T. H., Masatsugu, K., Becker, A. E., and Nakao, K. (1998). Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98, 2108-2116.
69. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
70. Jain,R. K. (2008). Taming vessels to treat cancer. Sci. Am. 298, 56-63.
71. Jain, R. K., Koenig, G. C., Dellian, M., Fukumura, D., Munn, L. L., and Melder, R. J. (1996). Leuko- cyte endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev. 15, 195-204.
72. Jain, S., Furness, P. N., and Nicholson, M. L. (2000). The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 69, 1759-1766.
73. Jain, S., Mohamed, M. A., Sandford, R., Furness, P. N., Nicholson, M. L., and Talbot, D. (2002). Sequential protocol biopsies from renal transplant recipients show an increasing expression of active TGF beta. Transpl. Int. 15, 630-634.
74. Johnson, D. W., Forman, C., and Vesey, D. A. (2006). Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton) 11, 306-312.
75. Kaminski, M., and Auerbach, R. (1988). Angiogenesis induction by CD-4 positive lymphocytes. Proc. Soc. Exp. Biol. Med. 188, 440-443.
76. Kanazawa, S., Tsunoda, T., Onuma, E., Majima, T., Kagiyama, M., and Kikuchi, K. (2001). VEGF, basic- FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am. J. Gastroenterol. 96, 822-828.
77. Kang, D. H., Joly, A. H., Oh, S. W., Hugo, C., Kerjaschki, D., Gordon, K. L., Mazzali, M., Jefferson, J. A., Hughes, J., Madsen, K. M., Schreiner, G. F., and Johnson, R. J. (2001a). Impaired angiogenesis in the rem- nant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J. Am. Soc. Nephrol. 12, 1434-1447.
78. Kang, D. H., Hughes, J., Mazzali, M., Schreiner, G. F., and Johnson, R. J. (2001b). Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J. Am. Soc. Nephrol. 12, 1448-1457.
79. Kang, D. H., Kanellis, J., Hugo, C., Truong, L., Anderson, S., Kerjaschki, D., Schreiner, G. F., and Johnson, R. J. (2002). Role of the microVascular endothelium in progressive renal disease. J. Am. Soc. Nephrol. 13, 806-816.
80. Kim, I., Moon, S. O., Kim, S. H., Kim, H. J., Koh, Y. S., and Koh, G. Y. (2001). Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM- 1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J. Biol. Chem. 276, 7614-7620.
81. Kim, Y. S., Hong, S. W., Choi, J. P., Shin, T. S., Moon, H. G.,Choi, E. J., Jeon, S. G., Oh, S. Y., Gho, Y. S., Zhu, Z., and Kim, Y. K. (2009). Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type 1 and type 17 T helper cells in the airways. J. Immunol. 183, 5113-5120.
82. Klagsbrun, M., and D'Amore, P. A. (1996). Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7, 259-270.
83. Koch, A. E., Harlow, L. A., Haines, G. K., Amento, E. P., Unemori, E. N., Wong, W. L., Pope, R. M., and Ferrara, N. (1994). Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. 152, 4149-4156.
84. Koch, A. E., Polverini, P. J., and Leibovich, S. J. (1986). Induction of neovascularization by activated human monocytes. J. Leukoc. Biol. 39, 233-238.
85. Kokudo, T., Suzuki, Y., Yoshimatsu, Y., Yamazaki, T., Watabe, T., and Miyazono, K. (2008). Snail is required for TGFbeta-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J. Cell. Sci. 121, 3317-3324.
86. Kreisel, D., Krupnick, A. S., Gelman, A. E., Engels, F. H., Popma, S. H., Krasinskas, A. M., Balsara, K. R., Szeto, W. Y., Turka, L. A., and Rosengard, B. R. (2002). Non- hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mech- anism of allorecognition. Nat. Med. 8, 233-239.
87. Laxmanan, S., Robertson, S. W., Wang, E., Lau, J. S., Briscoe, D. M., and Mukhopadhyay, D. (2005). Vascular endothelial growth factor impairs the functional ability of den- dritic cells through Id pathways. Biochem. Biophys. Res. Commun. 334, 193-198.
88. Lee, C. G., Link, H., Baluk, P., Homer, R. J., Chapoval, S., Bhandari, V., Kang, M. J., Cohn, L., Kim, Y. K., McDonald, D. M., and Elias, J. A. (2004). Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2- mediated sensitization and inflam- mation in the lung. Nat. Med. 10, 1095-1103.
89. Lee, S., Chen, T. T., Barber, C. L., Jordan, M. C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., Roos, K. P., and Iruela-Arispe, M. L. (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
90. Leibovich, S. J., Polverini, P. J., Fong, T. W., Harlow, L. A., and Koch, A. E. (1994). Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide- synthase-dependent effector mechanism. Proc. Natl. Acad. Sci. U.S.A. 91, 4190-4194.
91. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N. (1987). Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature 329, 630-632.
92. Leibovich, S. J., and Wiseman, D. M. (1988). Macrophages, wound repair and angiogenesis. Prog. Clin. Biol. Res. 266, 131-145.
93. Lemstrom, K. B., Krebs, R., Nykanen, A. I.,Tikkanen,J. M.,Sihvola,R. K.,Aal- tola, E. M., Hayry, P. J., Wood, J., Ali- talo, K., Yla-Herttuala, S., and Koskinen, P. K. (2002). Vascular endothe-lial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105, 2524-2530.
94. Leonard, E. C., Friedrich, J. L., and Basile, D. P. (2008). VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am. J. Physiol. Renal Physiol. 295, F1648-F1657.
95. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., and Fer- rara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
96. Li, J., Qu, X., and Bertram, J. F. (2009). Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin- induced diabetic mice. Am. J. Pathol. 175, 1380-1388.
97. Libby,P.,and Pober,J. S. (2001). Chronic rejection. Immunity 14, 387-397.
98. Majno, G. (1998). Chronic inflammation: links with angiogenesis and wound healing. Am. J. Pathol. 153, 1035-1039.
99. Malmstrom, N. K., Kallio, E. A., Rin-tala, J. M., Nykanen, A. I., Raisanen- Sokolowski, A. K., Paavonen, T., Lemstrom, K. B., and Koskinen, P. K. (2008). Vascular endothelial growth factor in chronic rat allograft nephropathy. Transpl. Immunol. 19, 136-144.
100. Mannon, R. B. (2006). Therapeutic targets in the treatment of allograft fibrosis. Am. J. Transplant. 6, 867-875.
101. Markwald, R. R., Fitzharris, T. P., and Smith, W. N. (1975). Structural analysis of endocardial cytodifferentiation. Dev. Biol. 42, 160-180.
102. Marumo, T., Schini-Kerth, V. B., and Busse, R. (1999). Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 48, 1131-1137.
103. Matsumoto, T., and Mugishima, H. (2006). Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. J. Atheroscler. Thromb. 13, 130-135.
104. Mayer, G. (2011). Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol. Dial. Transplant. 26, 1132-1137.
105. McDonald, D. M. (2001). Angiogenesis and remodeling of airway vasculature in chronic inflammation. Am. J. Respir. Crit. Care Med. 164, S39-S45.
106. Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R., and Olsen, B. R. (2010). Conversion of Vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406.
107. Melder, R. J., Koenig, G. C., Witwer, B. P., Safabakhsh, N., Munn, L. L., and Jain, R. K. (1996). During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2, 992-997.
108. Melter, M., Reinders, M. E., Sho, M., Pal, S., Geehan, C., Denton, M. D., Mukhopadhyay, D., and Briscoe, D. M. (2000). Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96,3801-3808.
109. Miao, H. Q., and Klagsbrun, M. (2000). Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev. 19, 29-37.
110. Mizui, M., Kumanogoh, A., and Kikutani, H. (2009). Immune semaphorins: novel features of neural guidance molecules. J. Clin. Immunol. 1, 1-11.
111. Mor, F., Quintana, F. J., and Cohen, I. R. (2004). Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J. Immunol. 172, 4618-4623.
112. Moulton, K. S., Melder, R. J., Dharnid- harka, V. R., Hardin-Young, J., Jain, R. K., and Briscoe, D. M. (1999). Angiogenesis in the huPBL-SCID model of human transplant rejection. Transplantation 67, 1626-1631.
113. Mukhopadhyay, D., Tsiokas, L., Zhou, X. M., Foster, D., Brugge, J. S., and Sukhatme, V. P. (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375, 577-581.
114. Nakao, A., Choi, A. M., and Murase, N. (2006). Protective effect of carbon monoxide in transplantation. J. Cell. Mol. Med. 10, 650-671.
115. Nykanen, A. I., Krebs, R., Saaristo, A., Turunen, P., Alitalo, K., Yla-Herttuala, S., Koskinen, P. K., and Lemstrom, K. B. (2003). Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 107, 1308-1314.
116. Oberbauer, R., Segoloni, G., Campistol, J. M., Kreis, H., Mota, A., Lawen, J., Russ, G., Grinyo, J. M., Stallone, G., Hartmann,A.,Pinto,J. R.,Chapman, J., Burke, J. T., Brault, Y., and Ney- lan, J. F. (2005). Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl. Int. 18, 22-28.
117. Osasan, S. A., de Freitas, D. G., Chang, J., Mengel, M., Halloran, P. F., and Sis, B. (2011). Microcirculation endothelial cell cycling is selectively increased in antibody- mediated rejection of kidney transplants, but not in other diseases. J. Am. Soc. Nephrol. 22, 103A.
118. Peng, W., Chen, J., Jiang, Y., Shou, Z., Chen,Y.,and Wang,H. (2008). Acute renal allograft rejection is associ- ated with increased levels of vascular endothelial growth factor in the urine. Nephrology (Carlton) 13, 73-79.
119. Pilmore, H. L., Eris, J. M., Painter, D. M., Bishop, G. A., and McCaughan, G. W. (1999). Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 67, 929-933.
120. Pober, J. S., Orosz, C. G., Rose, M. L., and Savage, C. O. S. (1996). Can graft endothelial cells initiate a host anti-graft immune response? Transplantation 61, 343-349.
121. Pober, J. S., and Sessa, W. C. (2007). Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 7, 803-815.
122. Polverini, P. J. (1997). Role of the macrophage in angiogenesis- dependent diseases. EXS 79, 11-28.
123. Rabelink,T. J.,Wijewickrama,D. C.,and de Koning, E. J. (2007). Peritubular endothelium: the Achilles heel of the kidney? Kidney Int. 72, 926-930.
124. Reinders, M. E., and Briscoe, D. M. (2002). Angiogenesis and allograft rejection. Graft 5, 96-101.
125. Reinders, M. E., Rabelink, T. J., and Briscoe, D. M. (2006). Angiogenesis and endothelial cell repair in renal disease and allograft rejection. J. Am. Soc. Nephrol. 17, 932-942.
126. Reinders, M. E., Sho, M., Izawa, A., Wang, P., Mukhopadhyay, D., Koss, K. E., Geehan, C. S., Luster, A. D., Sayegh, M. H., and Briscoe, D. M. (2003a). Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J. Clin. Invest. 112, 1655-1665.
127. Reinders, M. E., Fang, J. C., Wong, W., Ganz, P., and Briscoe, D. M. (2003b). Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 76, 224-230.
128. Romeo, P. H., Lemarchandel, V., and Tordjman, R. (2002). Neuropilin-1 Bruneau et al. The intragraft microenvironment in the immune system. Adv. Exp. Med. Biol. 515, 49-54.
129. Sarris, M., Andersen, K. G., Randow, F., Mayr, L., and Betz, A. G. (2008). Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28, 402-413.
130. Schena, F. P., Pascoe, M. D., Alberu, J., del Carmen Rial, M., Oberbauer, R., Brennan, D. C., Campistol, J. M., Racusen, L., Polinsky, M. S., Goldberg-Alberts, R., Li, H., Scarola, J., and Neylan, J. F. (2009). Con- version from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87, 233-242.
131. Schor, A. M., Canfield, A. E., Sut- ton, A. B., Arciniegas, E., and Allen, T. D. (1995). Pericyte differentiation. Clin. Orthop. Relat. Res. 81-91.
132. Shahbazi, M., Fryer, A. A., Pravica, V., Brogan, I. J., Ramsay, H. M., Hutchinson, I. V., and Harden, P. N. (2002). Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 13, 260-264.
133. Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
134. Sharma, V. K., Bologa, R. M., Xu, G. P., Li, B., Mouradian, J., Wang, J., Serur, D., Rao, V., and Suthanthi- ran, M. (1996). Intragraft TGF- beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int. 49, 1297-1303.
135. Shin, J. Y., Yoon, I. H., Kim, J. S., Kim, B., and Park, C. G. (2009). Vascular endothelial growth factor-induced chemotaxis and IL- 10 from T cells. Cell. Immunol. 256, 72-78.
136. Sho, M., Akashi, S., Kanehiro, H., Hamada, K., Kashizuka, H., Ikeda, N., Nomi, T., Kuzumoto, Y., Tsu- rui, Y., Yoshiji, H., Wu, Y., Hicklin, D. J., Briscoe, D. M., and Nakajima, Y. (2005). Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo. Transplantation 80, 717-722.
137. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia- initiated angiogenesis. Nature 359, 843-845.
138. Sidky, Y. A., and Auerbach, R. (1975). Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J. Exp. Med. 141, 1084-1100.
139. Sis, B., and Halloran, P. F. (2010). Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr. Opin. Organ Transplant. 15, 42-48.
140. Sis, B., Jhangri, G. S., Bunnag, S., Allanach, K., Kaplan, B., and Hal- loran, P. F. (2009). Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am. J. Trans- plant. 9, 2312-2323.
141. Steegh, F. M., Gelens, M. A., Nieman, F. H., van Hooff, J. P., Cleutjens, J. P., van Suylen, R. J., Daemen, M. J., van Heurn, E. L., Christiaans, M. H., and Peutz-Kootstra, C. J. (2011). Early loss of peritubular capillaries after kidney transplantation. J. Am. Soc. Nephrol. 22, 1024-1029.
142. Strieter, R. M., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., and Polverini, P. J. (1995a). Interferon gamma- inducible protein 10 (IP-10),a mem- ber of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 210, 51-57.
143. Strieter, R. M., Polverini, P. J., Arenberg, D. A., and Kunkel, S. L. (1995b). The role of CXC chemokines as regulators of angiogenesis. Shock 4, 155-160.
144. Suzuki, H., Onishi, H., Wada, J., Yamasaki,A.,Tanaka,H.,Nakano,K., Morisaki, T., and Katano, M. (2010). VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur. J. Immunol. 40, 197-203.
145. Suzuki, K., Kumanogoh, A., and Kikutani, H. (2008). Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 9, 17-23.
146. Takahashi, H., and Shibuya, M. (2005). The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. 109, 227-241.
147. Tanaka, H., Sukhova, G. K., and Libby, P. (1994). Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler. Thromb. 14, 734-745.
148. Tischer, E., Mitchell, R., Hartman, T., Silva,M.,Gospodarowicz,D.,Fiddes, J. C., and Abraham, J. A. (1991). The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954.
149. Tordjman, R., Lepelletier, Y., Lemarchandel, V., Cambot, M., Gaulard, P., Hermine, O., and Romeo, P. H. (2002). A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol. 3, 477-482.
150. Torry, R. J., Labarrere, C. A., Torry, D. S., Holt, V. J., and Faulk, W. P. (1995). Vascular endothelial growth factor expression in transplanted human hearts. Transplantation 60, 1451-1457.
151. Valujskikh, A., and Heeger, P. S. (2003). Emerging roles of endothelial cells in transplant rejection. Curr. Opin. Immunol. 15, 493-498.
152. Vos, I. H., and Briscoe, D. M. (2002). Endothelial injury: cause and effect of alloimmune inflammation. Transpl. Infect. Dis. 4, 152-159.
153. Walsh,D.A.,andPearson,C.I.(2001). Angiogenesisinthepathogenesisof inflammatoryjointandlungdiseases. ArthritisRes. 3, 147-153
154. Wang, L., Zeng, H., Wang, P., Soker, S., and Mukhopadhyay, D. (2003). Neuropilin-1-mediated Vascular permeability factor/vascular endothelial growth factor- dependent endothelial cell migration. J. Biol. Chem. 278, 48848-48860.
155. Watanabe, H., Mamelak, A. J., Wang, B., Howell, B. G., Freed, I., Esche, C., Nakayama, M., Nagasaki, G., Hick- lin, D. J., Kerbel, R. S., and Sauder, D. N. (2004).Anti-vascular endothelial growth factor receptor-2 (Flk- 1/KDR) antibody suppresses contact hypersensitivity. Exp. Dermatol. 13, 671-681.
156. Watanabe, H., Mamelak, A. J., Weiss, E., Wang, B., Freed, I., Brice, A. K., Wachtman, L., Gabrielson, K. L., Yokota, N., Hicklin, D. J., Ker- bel, R. S., Haas, M., and Sauder, D. N. (2005). Anti-vascular endothe-lial growth factor receptor-2 anti-body accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin. Cancer Res. 11, 407-409.
157. Wiseman, D. M., Polverini, P. J., Kamp, D. W., and Leibovich, S. J. (1988). Transforming growth factor- beta (TGF beta) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem. Biophys. Res. Commun. 157, 793-800.
158. Woywodt, A., Schroeder, M., Gwinner, W., Mengel, M., Jaeger, M., Schwarz, A., Haller, H., and Haubitz, M. (2003). Elevated numbers of circu- lating endothelial cells in renal transplant recipients. Transplantation 76, 1-4.
159. Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson,E.,Chandraker,A.,Yuan, X., Pu, W. T., Roberts, A. B., Neilson, E. G., Sayegh, M. H., Izumo, S., and Kalluri, R. (2007a). Endothelial-to- mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 13, 952-961.
160. Zeisberg, E. M., Potenta, S., Xie, L., Zeis-berg, M., and Kalluri, R. (2007b). Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibrob-lasts. Cancer Res. 67, 10123-10128.
161. Zeng, H., Dvorak, H. F., and Mukhopadhyay, D. (2001). Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) receptor-1 down-modulates VPF/ VEGF receptor-2-mediated endo- thelial cell proliferation, but not migration, through phosphatidyli- nositol 3-kinase-dependent pathways. J. Biol. Chem. 276, 26969-26979.
162. Zeng, H., Zhao, D., and Mukhopadhyay, D. (2002). Flt-1-mediated down- regulation of endothelial cell proliferation through pertussis toxin- sensitive G proteins, beta gamma subunits, small GTPase CDC42, and partly by Rac-1. J. Biol. Chem. 277, 4003-4009.
163. Zhang,J.,Silva,T.,Yarovinsky,T.,Manes, T. D., Tavakoli, S., Nie, L., Tellides, G., Pober, J. S., Bender, J. R., and Sadeghi, M. M. (2010). VEGF block- ade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling. Circ. Res. 107, 408-417.
164. Zhang, X., and Reed, E. F. (2009). Effect of antibodies on endothelium. Am. J. Transplant. 9, 2459-2465.
165. Zhao, Q., Egashira, K., Inoue, S., Usui, M., Kitamoto, S., Ni, W., Ishibashi, M., Hiasa Ki, K., Ichiki, T., Shibuya, M., and Takeshita, A. (2002). Vascular endothelial growth factor is necessary in the development of arterioscle- rosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation 105, 1110-1115.
166. Ziogas, A. C., Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Terpos, E., Rodolakis,A.,Vlahos,G.,Thomakos, N., Haidopoulos, D., Antsaklis, A., Dimopoulos, M. A., and Bamias, A. (2011). VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individ- uals via VEGF receptor type 2. Int. J. Cancer 130, 857-864.